Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition

被引:688
作者
Sun, SY
Rosenberg, LM
Wang, XR
Zhou, ZM
Yue, P
Fu, H
Khuri, FR
机构
[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Pharmacol, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Hematol & Oncol, Atlanta, GA 30322 USA
关键词
D O I
10.1158/0008-5472.CAN-05-0917
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mammalian target of rapamycin (mTOR) has emerged as an important cancer therapeutic target. Rapamycin and its derivatives that specifically inhibit mTOR are now being actively evaluated in clinical trials. Recently, the inhibition of mTOR has been shown to reverse Akt-dependent prostate intraepithelial neoplasia. However, many cancer cells are resistant to rapamycin and its derivatives. The mechanism of this resistance remains a subject of major therapeutic significance. Here we report that the inhibition of mTOR by rapamycin triggers the activation of two survival signaling pathways that may contribute to drug resistance. Treatment of human lung cancer cells with rapamycin suppressed the phosphorylation of p70S6 kinase and 4E-BP1, indicating an inhibition of mTOR signaling. Paradoxically, rapamycin also concurrently increased the phosphorylation of both Akt and eIF4E. The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process. The activated Akt and eIF4E seem to attenuate rapamycin's growth-inhibitory effects, serving as a negative feedback mechanism. In support of this model, rapamycin combined with LY294002 exhibited enhanced inhibitory effects on the growth and colony formation of cancer cells. Thus, our study provides a mechanistic basis for enhancing mTOR-targeted cancer therapy by combining an mTOR inhibitor with a PI3K or Akt inhibitor.
引用
收藏
页码:7052 / 7058
页数:7
相关论文
共 33 条
[11]   Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth [J].
Lachance, PED ;
Miron, M ;
Raught, B ;
Sonenberg, N ;
Lasko, P .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (06) :1656-1663
[12]   mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways [J].
Majumder, PK ;
Febbo, PG ;
Bikoff, R ;
Berger, R ;
Xue, Q ;
McMahon, LM ;
Manola, J ;
Brugarolas, J ;
McDonnell, TJ ;
Golub, TR ;
Loda, M ;
Lane, HA ;
Sellers, WR .
NATURE MEDICINE, 2004, 10 (06) :594-601
[13]   Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis [J].
Manning, BD .
JOURNAL OF CELL BIOLOGY, 2004, 167 (03) :399-403
[14]   Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR [J].
Neshat, MS ;
Mellinghoff, IK ;
Tran, C ;
Stiles, B ;
Thomas, G ;
Petersen, R ;
Frost, P ;
Gibbons, JJ ;
Wu, H ;
Sawyers, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) :10314-10319
[15]   Determinants of rapamycin sensitivity in breast cancer cells [J].
Noh, WC ;
Mondesire, WH ;
Peng, JY ;
Jian, WG ;
Zhang, HX ;
Dong, JJ ;
Mills, GB ;
Hung, MC ;
Meric-Bernstam, F .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :1013-1023
[16]   Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1 [J].
Pyronnet, S .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1237-1243
[17]   eIF4E activity is regulated at multiple levels [J].
Raught, B ;
Gingras, AC .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1999, 31 (01) :43-57
[18]   Regulation of cap-dependent translation by eIF4E inhibitory proteins [J].
Richter, JD ;
Sonenberg, N .
NATURE, 2005, 433 (7025) :477-480
[19]   Targeting the molecular target of rapamycin (mTOR) [J].
Rowinsky, EK .
CURRENT OPINION IN ONCOLOGY, 2004, 16 (06) :564-575
[20]   The biology and clinical relevance of the PTEN tumor suppressor pathway [J].
Sansal, I ;
Sellers, WR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2954-2963